Focus areas include bio-catalysis, process analytical technology, and better pharma operations.
International pharma giants GSK, Pfizer, and MSD signed a memorandum of understanding (MOU) with A*STAR and National University of Singapore (NUS) to establish the Pharma Innovation Programme Singapore (PIPS).
According to a speech by Trade and Industry minister S Iswaran, PIPS will combine the expertise of the public sector and industry players to improve manufacturing operations and technologies.
PIPS will focus on continuous manufacturing, bio-catalysis, process analytical technology, advanced process control, and enhanced pharmaceutical operations.
Iswaran's speech opened the Future of Manufacturing Summit @ Singapore, A*Star's two-week series on improving Singapore's industries.
Do you know more about this story? Contact us anonymously through this link.